Biotech News
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
investorrelations.sarepta.com2026-05-06 20:12 EST
Net product revenues for the first quarter 2026 totaled $330.5 million, consisting of $102.0 million of ELEVIDYS net product revenue and $228.6 million of PMO net product revenues Achieved GAAP and non-GAAP operating income of $358.4 million and $397.7 million for the first quarter 2026,